Challenges of management and therapy in patients with a functionally single ventricle after Fontan operation by Trojnarska, Olga & Ciepłucha, Aleksandra
119www.cardiologyjournal.org
REVIEW ARTICLE
Cardiology Journal
2011, Vol. 18, No. 2, pp. 119–127
Copyright © 2011 Via Medica
ISSN 1897–5593
Address for correspondence: Olga Trojnarska, MD, PhD, 1st Department of Cardiology, University of Medical Sciences,
ul. Długa 1/2, 61–848 Poznań, Poland, tel/fax: +48 61 854 91 46, +48 61 852 94 72, e-mail: olgatroj@wp.pl
Received: 27.04.2010 Accepted: 21.01.2011
Challenges of management and therapy in
patients with a functionally single ventricle
after Fontan operation
Olga Trojnarska, Aleksandra Ciepłucha
1st Department of Cardiology, University of Medical Sciences, Poznań, Poland
Abstract
Forty years ago, Fontan and Baudet performed the first life-saving operation on a patient with
a functionally single ventricle. This multi-stage procedure established the connection between
systemic venous circulation and pulmonary arteries. As a consequence, the pulmonary circula-
tion is supplied in a passive way, whereas the single ventricle pumps the blood into the systemic
circulation only.
Over the years, the technique of creating the abovementioned vascular connections has under-
gone several modifications. Due to the fundamental non-physiological hemodynamic relations
between arterial pulmonary and systemic venous pressures, numerous complications can be
observed in these patients including: supraventricular arrhythmias, thromboemboli, hepatic
dysfunction, protein-losing enteropathy, heart failure, worsening cyanosis, systemic venous
collateralization, and pulmonary arteriovenous malformations, as well as connective tissue
lesions in bronchi.
Although based on an ingenious concept, the operation remains of a palliative character.
Occasionally, heart transplantation is the ultimate resolution. Pharmacological therapy, and
surgical conversion, often appear to be ineffective. However, this procedure has enabled many
patients to reach adulthood and enjoy their lives to the full. This fact poses a great challenge for
cardiologists wishing to become more knowledgeable and experienced as regards such patients,
if we are not to waste such fabulous surgical achievements. (Cardiol J 2011; 18, 2: 119–127)
Key words: Fontan operation, long-term follow-up, complications, management
Introduction
A palliative procedure that has been performed
since 1971, named after Fontan and Baudet, is the
method of treatment for patients with a functional-
ly single ventricle [1]. A diagnosis of univentricu-
lar heart includes the broad category of congenital
cardiac malformations, characterized by both atria
related entirely, or almost entirely, to one functio-
nally single ventricular chamber. The discussed pro-
cedure was first designed and introduced as a mana-
gement for tricuspid atresia, which, actually, is the
commonest form of univentricular heart. The ratio-
nale for this operation is to reduce the volume and
pressure overload of the single ventricle and to
normalize blood oxygenation. This is achieved by
creating a complete separation of the pulmonary
circulation from the systemic circulation [2, 3].
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Fontan operation
The procedure is accomplished in stages, with
the first step aimed at supplying an adequate pul-
monary perfusion. A decreased pulmonary blood
flow caused by a significant pulmonary stenosis
requires an arterial systemic-to-pulmonary connec-
tion to be performed (modified Blalock-Taussig
shunt). In patients with unrestrictive pulmonary
blood flow, an initial palliation may consist of pul-
monary artery banding, which unfortunately has
been associated with adverse outcomes late after
the Fontan procedure [4].
At around the sixth month of life, a procedure
termed a Glenn shunt is performed, in which a bi-
directional cavopulmonary anastomosis (superior
vena cava — pulmonary artery) is created in order
to reduce volume overload of the single ventricle.
Concurrently, the pulmonary perfusion evolves
from the fetal high-resistant into the low-resistant
circulation. The Fontan procedure is completed la-
ter, some time between 18 months and four years
of age, thereby separating pulmonary from systemic
circulation. The classic Fontan procedure involves
a valved conduit between the right atrium and pul-
monary artery. However, the specificity of circula-
tion created in this way and its physiology require
proper selection of patients strictly fulfilling the
criteria originally called the ‘Choussat command-
ments’. The most important of these, beside the
patient’s age, are: low pulmonary vascular resis-
tance (below 4 Wood units/m2 body surface area),
sinus rhythm, preserved systolic function of the
single ventricle, absence of a significant atrioven-
tricular regurgitation, normal systemic venous re-
turn, and normal right atrium volume as well as
absence of pulmonary artery distortion [5]. The
principle of the operation is to create a direct con-
nection between systemic venous circulation (ve-
nae cavae superior and inferior) and pulmonary ar-
teries without an interposed subpulmonary ventri-
cle. As a consequence, the blood flows into the lungs
in a passive way. Thus, adequate pulmonary perfu-
sion is achieved, as well as a decrease in volume
overload of the single ventricle, now responsible
only for supplying the systemic circulation.
Modifications of Fontan operation
Since 1971, many modifications of the Fontan
procedure have been introduced to encompass se-
veral forms of palliative surgery that divert systemic
venous return to the pulmonary artery [1]. Most
adults encountered today will have had a modified
Fontan procedure based on creation of direct anas-
tomosis of the right atrium to pulmonary artery.
In 1987, de Leval proposed a major variation
that consisted of an end-to-side anastomosis of the
superior vena cava to the right pulmonary artery,
a composite intraatrial tunnel with the right atrial
wall and a prosthetic patch to channel the inferior
vena cava to the transected superior vena cava [6].
Total cavopulmonary connection (TCPC) may also
be accomplished by means of an extracardiac tun-
nel, where blood from the inferior vena cava flows
directly to the pulmonary artery via an external con-
duit [7]. Fontan pathways are currently fenestrat-
ed by creation of an interatrial communication,
which may be beneficial early after surgical proce-
dure (Figs. 1, 2) [8]. At a later stage, fenestration
Figure 2. Unbalanced common atrioventricular canal
after the Fontan operation — a four-chamber view with
color Doppler imaging; RV — right ventricle; LV — ru-
dimentary left ventricle; FIC — fenestrated intraatrial
conduit; IT — tricuspid insufficiency.
Figure 1. Unbalanced common atrioventricular canal
after the Fontan operation — a four-chamber view;
RV — right ventricle; LV — rudimentary left ventricle;
FIC — fenestrated intraatrial conduit; AV valve — common
atrioventricular valve.
121
Olga Trojnarska, Aleksandra Ciepłucha, Forty years’ experience of Fontan operation
www.cardiologyjournal.org
can be closed by transcatheter approach. The modi-
fications presented above resulted from a search
for the optimal solution that would enable function-
ing of the hemodynamic system created by Fontan,
where the systemic venous pressure provides the
only impetus for blood inflow to the lungs and, as
a consequence, safeguards cardiac output. Such a si-
tuation is possible only if the pulmonary arterial
pressure is decreased at the expense of a small in-
crease in the systemic venous pressure.
Longstanding observations
Long-term follow-up proves beyond any doubt
that the Fontan operation is based on the correct
concept. Before the implementation of this treat-
ment, 90% of children with a functionally single
ventricle died before their first birthday [9]. In the
most comprehensive follow-up, comprising only
83 non-operated patients with a single morpholo-
gically left ventricle, it was observed that 70% of
them died before their sixteenth birthday [10].
A right ventricular morphology entailed an even
worse prognosis, as only 50% of children survived
more than four years after diagnosis [11]. In this
context, patients after a Fontan operation have
a considerably better prognosis, with 12-year survival
having been observed in 83% of patients operated on
using the method of atriopulmonary connection [12]
and ten-year survival has been reported in 91% of
patients in whom the lateral tunnels technique was
applied [13].
Khairy et al. [14] even described a 20-year sur-
vival rate of 82.6% of patients, and unexpectedly
found no differences among patients operated on by
various methods. The presented analysis demon-
strated that the risk factors for death in this popu-
lation included protein-losing enteropathy (a com-
plication discussed further in this paper), single
morphologically right ventricle and increased right
atrial pressure.
Complications after Fontan procedure
The modifications of Fontan operation still re-
main an intellectual challenge for cardiac surgeons.
There are some unavoidable complications, result-
ing from the fundamental non-physiological hemo-
dynamic relations between arterial pulmonary and
systemic venous pressures, which eventually con-
stitute the physiology of the so-called ‘failing Fon-
tan’. Consequently, potential complications are nu-
merous and include arrhythmias, thromboemboli,
hepatic dysfunction, protein-losing enteropathy,
heart failure (HF), worsening cyanosis, systemic
venous collateralization, pulmonary arteriovenous
malformations and connective tissue lesions in
bronchi.
Rhythm and conduction disturbances
Supraventricular arrhythmia is a common
cause of hospitalization among patients with
a univentricular heart after Fontan. Its frequency
increases steadily with the patient’s age and the
post-operative interval, with at least 50% of patients
experiencing atrial tachycardia by 20 year follow-up
[15]. The commonest mechanism for symptomatic
tachycardia is macroreentry within atrial muscle
[16], the so-called ‘intra-atrial reentrant tachycar-
dia’ or ‘incisional tachycardia’. That kind of arrhyth-
mia is usually slower than a typical atrial flutter
which may be encountered in a structurally normal
heart, and is a consequence of the cardiosurgical
intervention as well as of intrinsic histopathological
features of the atrium. Histopathological examina-
tion of the atrial muscle in patients with tricuspid
atresia has shown an abnormal atrial fiber array that
may predispose to the slowing of conduction ne-
cessary for reentrant rhythms [17].
Other elements contributing to arrhythmia are:
anatomic structures such as orifices of inferior and
superior venae cavae, atrial septal defect or the os
of the coronary sinus, further compounded either
by the atrial suture lines or the atriopulmonary
anastomosis [16]. Moreover, residual hemodynamic
abnormalities cause a distention of atrial wall tis-
sue, which subsequently leads to sinus node dys-
function. This chain of pathological conditions pre-
disposes to an irregular atrial rhythm, which is
a trigger of supraventricular tachycardia. According
to the analysis performed, factors conducive to the
discussed arrhythmia in patients after Fontan pro-
cedure are: older age at the time of surgery, sinus
node dysfunction, early post-operative arrhythmias
and anatomy of double inlet left ventricle [18]. Su-
praventricular arrhythmia complicating the clinical
course gives an incentive to seek new operative
techniques. The lateral tunnel method, promising
during the initial follow-up period, has been proven
ineffective in protecting against progression of ar-
rhythmias in the long run [19]. A modification in-
cluding creation of an extracardiac tunnel, thus mini-
mizing the number of atrial sutures, results in
a lower incidence of arrhythmia, although post-ope-
rative follow-up of patients is still scarce [20]. An
extracardiac tunnel, however, precludes an ablation
procedure. Patients with a significant atrioventri-
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cular regurgitation may develop a ‘left-atrial’ arrhyth-
mia which is an atrial fibrillation. The presence of
supraventricular arrhythmia is a common cause of
aggravation of HF and emergence of thromboem-
bolic complications, and therefore requires vigor-
ous treatment.
The recently published survival analysis in
a Fontan population revealed a steadily increasing
risk of sudden death which could be a consequence
of either intraatrial reentrant tachycardia with rate
1:1 conduction, or ventricular arrhythmia, which is
a frequent complication of HF itself [14]. Therefore,
acute onset of tachycardia is an indication for ur-
gent cardioversion. A typical prior anticoagulative
management is not required [21], as the risk of sud-
den death in this particular group of patients is enor-
mous. Transesophageal echocardiography also does
not increase the likelihood of avoiding embolic com-
plications [16]. Treatment of the discussed arrhyth-
mia still remains empirical, based on the experts’
opinion. There are no available studies conducted
according to Evidence Based Medicine (EBM)
rules. Typically, beta blockers and digoxin are used
as they lack negative inotropic effects [22]. Amio-
darone is not recommended by some authors be-
cause of its thyroid and pulmonary side effects.
Others, in turn, advocate its broad application, be-
cause it does not impair the single ventricle systolic
function [23].
One must bear in mind, however, that most
antiarrhythmic drugs reduce heart rate, which may
subsequently lead to a drop of cardiac output, poor-
ly tolerated by patients with a single ventricle. The
occurrence of supraventricular arrhythmia may be
the first indicator for hemodynamic complications
of Fontan circulation. These are caused by a rise in
blood pressure at any level (stenosis of pulmonary
veins, arteries or artificially created anastomoses,
presence of newly emerged arteriovenous collate-
rals) and should be investigated either with nonin-
vasive or angiographic examination and dealt with
as soon as possible [24, 25]. Unfortunately, effec-
tive elimination of cardiac arrhythmia after hemo-
dynamic improvement is achieved only in one third
of Fontan patients [16]. A surgical conversion from
the atriopulmonary connection to the intra- or extra-
cardiac TCPC with concomitant cryoablation or
Maze procedure of atrial walls seems well-justified
in such clinical situations [26, 27]. In extreme cas-
es, difficult to control arrhythmias may require heart
transplantation [25, 26, 28].
An encouraging method of treatment for su-
praventricular arrhythmia is radiofrequency abla-
tion. This remains, however, a great challenge for
electrophysiologists. Limitations of the procedure
in Fontan patients include: diversity of circulating
stimuli, difficult approach to the atrium, anatomi-
cal complexity and uniqueness. The effectiveness
of this procedure reaches 80% [26, 29]. Unfortu-
nately however, the recurrence of tachycardia
during short follow-up has been reported as 30–
–66% [26, 30]. As mentioned above, bradycardia,
either iatrogenic or caused by sinus node dysfunc-
tion, might be a triggering factor for supraventri-
cular arrhythmia.
Therefore, according to some authors [31], it
is justifiable to implant epicardial electrodes during
the initial operation. The need for permanent heart
pacing derives also from the fact that loss of sinus
rhythm caused by sinus node dysfunction occurs
frequently, and increases in frequency with a longer
duration of follow-up. Due to lack of access to the
right ventricle, epicardial stimulation is utilized in
most cases, while dual-chamber stimulation is im-
planted in extremely experienced centers only
(with one electrode placed epicardially, the other
in the sinus venosus) [25, 26, 32].
Thromboembolic complications
Thrombotic events occur in 3% to 33% of Fon-
tan patients, apparently the highest prevalence
among all groups of adults with congenital heart
disease. Moreover, thromboembolism is probably
the leading cause of death among these patients
[33–38]. Its pathogenesis in Fontan patients is still
a matter of debate. This condition contributes to the
failure of Fontan circulation and may occur with
increased frequency in ‘failing’ Fontan circulation
[2, 33, 34]. There has been a report of a sharp in-
crease in risk for thromboembolic death 15 years
after Fontan surgery [14]. The underlying hemo-
dynamic mainstay of these complications includes
distended and sluggish Fontan pathways and atrial
arrhythmia conducive to hemostasis and hyper-
coagulable states. The latter include decreased le-
vels of protein C, protein S, antithrombin III, factors
II and X, as well as increased platelet reactivity [37].
Concurrently, a moderate factor VII deficiency has
been described in these patients, something which
should predispose to bleeding, rather than to coagu-
lation, therefore making the pathogenesis of throm-
boembolic complications even more complex [33].
Clotting factor abnormalities are to a large extent
the result of hepatic impairment caused by hemo-
dynamic complications. Specifically, in patients after
Fontan operation, hepatic congestion and cirrhosis
are common, unlike hepatic adenoma and carcinoma
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which seldom appear [2]. In the so-called Fontan
circuit, surgically created pathways between the
venae cavae and the pulmonary arteries are the
commonest places for thrombus formation which
may further embolize or extend into the pulmonary
arteries [33]. Thrombi may also originate in the
pulmonary venous pathway, systemic ventricle or
ligated pulmonary artery. The presence of intra-
cardiac communication (fenestration) poses a threat
of paradoxical embolism. In such clinical situations,
morbidity occurs principally in the form of embo-
lism in the central nervous system [34]. Risk fac-
tors of thromboembolic complications in the ana-
lyzed population are still unspecified, probably due
to the anatomical diversity of the study group and
the constantly changing methods of surgical treat-
ment. A correlation between thromboembolism and
factors including age at operation, type of procedure
performed, low cardiac output, arrhythmia, poly-
cythemia [37] or fenestration [33, 36, 37] remains
unproved despite the pathophysiological justifica-
tion and probability of event coincidence. Pulmo-
nary artery stump is the only factor of proven un-
desirable significance [36]. All these facts may con-
tribute to a lack of efficient treatment of the
mentioned complications. Administration of he-
parin, coumarin derivatives, aspirin, or a combina-
tion of all of these, or not taking any of them, does
not influence therapy outcomes [33–35]. Lately,
however, there have appeared even more reports
recommending coumarin derivatives, especially in
the presence of a dense spontaneous echocontrast
in the right atrium as well as in the cohort of pa-
tients operated on using more recent techniques
[38]. It has been proven that one of the risk factors
for death in this population is no anticoagulant the-
rapy taken, which is an argument justifying appli-
cation of such treatment [14].
Protein-losing enteropathy
A condition particularly hazardous for develo-
ping thromboembolic events is protein-losing ente-
ropathy (PLE), a typical post-Fontan complication.
It occurs at an incidence of 1.5% to 11%, with on-
set reported to range from as early as one month to
20 years (mean of approximately seven years) af-
ter Fontan operation [39–41].
The probable cause of PLE derives from the
essence of Fontan circulation based on the chroni-
cally elevated right atrial pressure with the subse-
quently increased inferior vena caval and portal vein
pressures. This elevation in abdominal venous pres-
sure presumably leads to intestinal congestion, lym-
phatic obstruction and enteric protein loss [39].
Additionally, a univentricular heart often develops
poor compliance and diastolic dysfunction, which
subsequently contribute to low cardiac output. This
situation in the face of elevated venous pressure
predisposes the patients to mesenteric ischemia,
which results in intestinal mucosal injury culminat-
ing in the onset of enteric protein losses. At the
same time, it has been observed that not all patients
with PLE have exhibited increased systemic venous
pressure, which suggests a more complex mecha-
nism of the discussed phenomenon [25, 39, 41].
It is assumed therefore that the additional
cause of intestinal epithelial membrane injury is
a hitherto unknown infectious agent [42]. Protein-
-losing enteropathy is more frequent among patients
with a single morphologically right ventricle and
those with longer cardiopulmonary bypass time.
This last finding suggests a potential role of the
perioperative cardiac injury in the pathogenesis of
this complication. On the other hand, it may serve
as an indicator for more difficult operation due to
anatomic complexity that distinguishes higher risk
patients [40]. Laboratory findings show PLE pa-
tients exhibit low levels of serum proteins, albumins
in particular, and increased faecal alfa1 antitrypsin
levels [24, 25]. The degree of clinical manifestation
varies widely, from clinically asymptomatic to
chronically debilitating. The commonest clinical
presentation is fluid retention that occurs as the
result of reduced vascular oncotic pressure due to
enteric protein loss and manifests itself by means
of peripheral edema, fatigue, pericardial and pleu-
ral effusions as well as ascites. These conditions are
often concomitant with chronic diarrhea [2, 41]. As
a consequence of chronic loss of immunoglobulins
and intestinal lymphangiectasia resulting in lympho-
cyte depletion, patients are susceptible to infec-
tions. Occasionally, PLE is demonstrated by
a thromboembolism as a consequence of anticoagu-
lant proteins loss [39, 43]. The prognosis for pa-
tients with PLE is very poor, with mortality rates
of 30% at two years and 50% during the following
five [39, 40, 43]. Treatment of proven effectiveness
does not exist and any therapeutic successes re-
main anecdotal. Hence, it is essential to exclude all
potential hemodynamic and arrhythmic complica-
tions that would require medical intervention. Un-
fortunately, PLE may manifest itself even with op-
timal Fontan palliation. The medical therapy of this
complication is three-directional and involves mem-
brane stabilization, improvement in ventricular
function and protein homeostasis through nutritio-
nal support and protein replacement treatment.
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Due to the pathomechanism of PLE, an intra-
venous albumin supplementation does not provide
any stable effect. Therefore, securing a high-pro-
tein diet and, due to fat malabsorption from intesti-
nal lymphatic dilatation, a high medium-chain tri-
glycerides diet, is essential [43, 44]. Hemodynam-
ic improvement is achieved mainly by the combined
use of diuretic therapy and attempts to augment
cardiac output by reduction of afterload or by means
of inotropic support. Treatments comprise angio-
tensin-converting enzyme (ACE) inhibitors, phos-
phodiesterase inhibitors or beta-blockers. In some
patients with PLE, aldosterone-receptor antagonist
therapy reduces proteinuria. But whether the ef-
fect is secondary to changes in intraventricular vo-
lume and pressure, or is achieved through direct
mineralocorticoid receptor antagonism remains
unclear [45]. It has been reported that PLE may
sometimes be a complication of autoimmune and
inflammatory processes such as those seen in the
course of lupus erythematosus and sarcoidosis,
suggesting an inflammatory response as an under-
lying cause of protein intestinal losing. This find-
ing was the basis for the administration of cortico-
steroids (25–60 mg of prednisolone per day) with
quite a good effect, although confirmed only by an-
ecdotal reports. In addition to an increase in albu-
min levels, this therapy improves levels of immu-
noglobulin G [39]. Unfortunately, discontinuing ste-
roidotherapy results in recurrence of symptoms
[46]. Chronically elevated pressure in the venous
vascular bed is thought to interfere with the pro-
duction and distribution of sulfated glycosaminogly-
cans such as heparin sulfate which are involved in
the regulation of albumin losses. Therefore, at-
tempts have been made at heparin therapy with,
according to some authors, a significant clinical
improvement resulting from the inhibition of pro-
tein escape [47].
In patients with PLE, hypocalcemia may be
a clinical consequence of hypoproteinemia and vita-
min D deficiency caused by fat malabsorption. Cal-
cium supplementation enhanced by administration
of vitamin D causes normalization of this element
in serum levels. Moreover, in some patients with
PLE this treatment, through an unknown mecha-
nism, reduces proteinuria and visibly improves pa-
tients’ clinical state [48]. Lymphocyte and immu-
noglobulin loss predispose to considerable immune
deficiency. Unfortunately, immunoglobulin supple-
mentation yields only a short-term improvement,
meaning that vaccinations are recommended [49].
Thus, periodic administration of fresh frozen plas-
ma in order to replenish stores of proteins C and S,
as well as antithrombin III to avoid a prothrombo-
tic state, would be justified [33].
Heart failure
Subsequent to Fontan palliation, the separation
of systemic circulation from pulmonary circulation
is designed to reduce the volume overload of the
single ventricle. Nevertheless, the single ventricle
has to sustain systolic function securing both circu-
lations, which inevitably leads to its insufficiency.
A Fontan operation is performed in several
stages in order to enable reduction in ventricular
size and wall thickness, which in turn increases
ventricular contractility. However, systolic and dia-
stolic functions of the single ventricle remain im-
paired as a result of the preoperative chronic vo-
lume overload as well as the typically co-existing,
abovementioned, aortopulmonary collaterals [50].
Impaired exercise capacity in analyzed patients is
also associated with reduced vital capacity, high
residual volume-to-total lung capacity ratio and
skeletal muscle dysfunction [51]. Such a condition
manifests itself by the typical HF symptoms: exer-
cise intolerance, dyspnea and fatigue. Objective
quantification via a cardiopulmonary exercise test
confirms a significantly reduced aerobic capacity
[52]. It has been proven that higher oxygen uptake
is characteristic of patients with a single morpho-
logically left ventricle [53]. Heart failure is an ac-
knowledged risk factor for death in patients after
Fontan operation, especially concerning patients
with a single morphologically right ventricle [14,
41]. Treatment of this condition is based on the
rules applying to the general population of patients,
completed with experts’ opinions, retrospective
data collection and small, single-center studies.
Similarly to the case of antiarrhythmic treatment,
there are no available studies into HF therapy in
this group of patients supported by EBM. Angio-
tensin-converting enzyme inhibition is frequently
used in patients with failing Fontan circulation. Ele-
vated levels of hormones that modulate fluid ho-
meostasis including aldosterone, renin, angiotensin
and antidiuretic hormone have been demonstrated
in most Fontan patients [25]. Exceptionally high
levels of the abovementioned hormones characte-
rize HF [54]. Application of ACE inhibitors reduces
vasoconstriction, subsequently decreasing end-dia-
stolic pressure and improving cardiac output. An-
other group of drugs used in chronic HF are beta-
-blockers. They diminish the increased adrenergic
activation typically encountered in HF that leads to
myocardial hypertrophy and apoptosis.
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One must bear in mind, however, that negative
chrono- and dromotropic effects of beta-blockers are
particularly harmful for this population. On the other
hand, it has been observed that these drugs, com-
bined with ACE inhibitors or in monotherapy, usu-
ally lessen symptoms and lower mortality [55, 56].
Fluid retention as the effect of HF requires admini-
stration of loop diuretics. Use of spironolactone is
also well-advised. When applying dehydrating the-
rapy, sometimes necessarily aggressive, one must
remember to sustain an appropriate preload, which
in this specific group of patients is crucial by means
of preserving the cardiac output. Some authors ad-
vocate the use of nesiritide, a recombinant B-natriu-
retic peptide, as a new and promising medication
in the therapy of acute HF. It acts through regula-
tion of vascular tone and fluid homeostasis, causes
arterial and venous dilatation without reflex tachy-
cardia, and possesses lusiotropic properties, all of
which improve cardiac output. Although this par-
ticular group of patients would enormously benefit
from such therapeutic effects, clinical experience
of applying nesiritide in congenital heart disease is
unfortunately negligible [24]. In acute HF, some
authors recommend inotropes — phospohodie-
sterase inhibitors [25].
Lastly, advanced HF, usually accompanied by
the above clinical complications which constitute the
physiology of ‘failing Fontan’, is an indication for the
revision of the atriopulmonary connection to the la-
teral or extracardiac cavopulmonary connection. It is
performed under the assumption that coronary per-
fusion will be improved by placing the coronary si-
nus in the lower pressure atrium, and that the fluid
dynamics of the cavopulmonary type connection re-
duces energy loss [57]. Heart transplantation is con-
sidered to be the ultimate resolution, yet practically
it is not widely available due to technical problems
of a re-sternotomy and markedly altered heart ana-
tomy, as well as limited donor supply [57, 58].
Cyanosis
The vast majority of Fontan patients present
with normal, or near normal, oxygen saturation
[2, 25, 41]. A small degree of desaturation (usually
exceeding 94%) originates from the anatomical con-
ditions deliberately created in a Fontan operation,
where venous blood from the sinus venosus flows
into the atrium and mixes there with oxygenated
blood from pulmonary veins. Occasionally, a giant
right atrium compresses the pulmonary vein [2, 59].
An increase in the right atrial pressure may also be
responsible for the development of vascular Fon-
tan-systemic connections. Venovenous collaterals,
in turn, are frequently observed in patients after
bidirectional cavopulmonary anastomosis [59]. In
advanced cases, cathether embolization of these
blood vessels should be considered. Cyanosis may
also result from a right-to-left shunt through an
atrial fenestration or a leak of the inferior vena cava
to right pulmonary artery baffle. Both types of this
intracardiac communication, after an earlier hemo-
dynamic evaluation, may be safely closed by devi-
ces, thereby reducing subsequent need for anticon-
gestive medication and improving oxygenation [60].
Desaturation is also an effect of progressive drop
in single ventricle competence [50]. Moreover,
a hallmark of Fontan pulmonary circulation is the
non-pulsatile flow that results in a reduced release
of endogenous nitric oxide, an endothelial vasodi-
latator, along with an increased activity of endo-
thelin. In some patients, it may cause a progressive
rise in pulmonary pressure. A rare, but mostly le-
thal, pulmonary complication is the so-called plas-
tic bronchitis, in which protein deposits are present
in bronchi. Urokinase therapy remains a dramatic
attempt at treatment in such cases.
Pregnancy
Hemodynamic changes observed during preg-
nancy (increased cardiac output, heart rate and
stroke volume, with simultaneous drop in vascular
resistance) create extremely disadvantageous con-
ditions for women after the Fontan operation. In
fact, dependence on the venous return in these pa-
tients poses some limitation on the ability to secure
an adequate cardiac output. For this reason, there
have been few case studies published of pregnan-
cies after Fontan operation [61–64]. Fortunately,
there are no reports of maternal deaths; however,
an exacerbation of arrhythmia and a transient de-
terioration of HF are frequent. Moreover, there is
a serious threat of thromboembolism and parado-
xical emboli, if the Fontan is fenestrated [25]. The
ratios of miscarriages and number of lower birth
weight newborns are higher than in the healthy
population. Despite the anticipated complications,
pregnancy in women after Fontan palliation is not
contraindicated. It must be, however, carefully
planned and managed in specialist centers [63, 64].
When deciding on motherhood, women with a sin-
gle ventricle after cardiac surgery must be made
aware of their life expectancy to make informed
choices as to their ability to raise the child.
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Conclusions
The Fontan operation and its variable modifi-
cations are the most remarkable and important de-
velopments in cardiac surgery in recent decades.
This ingenious approach, although of a palliative
nature only, has allowed for the survival of patients
with heart anomalies previously considered lethal.
Today, this newly emerged patient population re-
presents a challenge for ‘adult’ cardiologists, if we
are not to waste such fabulous surgical results.
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